European Stocks Steady as Novartis Shares Plunge 10% After Clinical Setbacks
Macro·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
European stocks were steady on Tuesday, with heavyweight Novartis AG weighing on the market after suffering its third clinical-trial setback in a week.
The decline in Novartis shares contributed to a muted performance across European markets, highlighting the impact of the company's recent challenges.
Novartis
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“European stocks were steady on Tuesday, with heavyweight Novartis AG weighing on the market after suffering its third clinical-trial setback in a week.”
Bloomberg — European Stocks Muted as Novartis Shares Fall Most on Record